Rheumatology Scientific References
Fertility | Women's Health | Urology | Rheumatology | General Health
LATEST RESEARCH UPDATE: A 2018 systematic review and meta-analysis found that omega-3 polyunsaturated fatty acid (PUFA) consumption significantly improved several markers of rheumatoid arthritis (RA) severity. Twenty Randomized Clinical Trials (RCTs) with 1288 RA patients were included in the analysis. Participants supplemented with omega 3 fish oils for at least 3 months, and all patients maintained their conventional drug treatment throughout. Omega-3 intake significantly improved early morning stiffness, tender joint count, erythrocyte sedimentation rate, and pain scale. For more information check out the PubMed abstract.
Joint Health
(2017/05) Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT).
(2016/11) Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study.
(2015/01) Chondroitin for osteoarthritis.
(2013/03) Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence?
(2011/11) Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center.
(2011/06) Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.
(2010/06) Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration.
(2010/06) Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study
(2009/02) Long-Term Effects of Chondroitins 4 and 6 Sulfate on Knee Osteoarthritis
(2008/09) Potential effects of chondroitin sulfate on joint swelling: a GAIT report.
(2007/01) Symptom and Structure Modifying Properties of Chondroitin Sulfate in Osteoarthritis
(2005/03) Chondroitins 4 and 6 Sulfate in Osteoarthritis of the Knee
(2008/09) Potential effects of chondroitin sulfate on joint swelling: a GAIT report.
(2007/01) Symptom and Structure Modifying Properties of Chondroitin Sulfate in Osteoarthritis
(2005/03) Chondroitins 4 and 6 Sulfate in Osteoarthritis of the Knee
(2018/09) Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis.
(2013/06) Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials.
(2012/06) Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties.
(2011/11) Statement on the safety of glucosamine for patients receiving coumarin anticoagulants
(2011/07) Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial.
(2011/04) The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature.
(2009/04) Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database
(2011/01) A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals.
(2009/04) Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized controlled trial.
(2007/03) Current role of glucosamine in the treatment of osteoarthritis. Review
(2006/11) Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis
(2005/01) Glucosamine therapy for treating osteoarthritis
(2003/12) Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate.
(2016/10) Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative.
(2016/01) Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
(2015/11) Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee.
(2013/12) Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis.
(2010/09) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.
(2010/03) The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.
(2010/01) Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis.
(2009/11) The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation.
(2009/01) A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis
(2008/10) The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.
(2006/02) Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis
(2006/02) Nutritional Supplements for Knee Osteoarthritis - Still No Resolution
(2003/07) Structural and Symptomatic Efficacy of Glucosamine and Chondroitin in Knee Osteoarthritis
Immune Health
(2015/06) Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).
(2013/05) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
(2010/09) Folate supplementation during methotrexate therapy for rheumatoid arthritis.
(2009/03) Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review.
(2009/01) Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity.
(2004/12) Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement.
(2002/06) Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.
(2001/07) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.
(1998/01) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A meta analysis of randomized controlled trials.
(2018/01) Intake of ω-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A systematic review and meta-analysis.
(2017/09) Omega-3 Fatty Acids in Rheumatic Diseases: A Critical Review.
(2017/07) Effect of ω-3 polyunsaturated fatty acids on arthritic pain: A systematic review.
(2017/06) Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study.
(2015/11) The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial.
(2015/09) Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis.
(2015/01) Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
(2012/06) Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis.
(2006/10) Reduction of Cardiovascular Risk Factors with Longterm Fish Oil Treatment in Early Rheumatoid Arthritis
(2003/01) Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis.
(1994/06) Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study.
(1990/06) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects.
(2018/01) Prevalence of depression and anxiety in rheumatoid arthritis patients and their associations with serum vitamin D level.
(2017/07) Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study.
(2017/06) Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis.
(2017/06) Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study.
(2017/01) The Role of 25-Hydroxyvitamin D as a Predictor of Clinical and Radiological Outcomes in Early Onset Rheumatoid Arthritis.
(2016/11) Prevalence of vitamin D deficiency in rheumatoid arthritis and association with disease activity and cardiovascular risk factors: data from the COMEDRA study.
(2016/09) Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis.
(2016/03) Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome.
(2015/08) Vitamin D Status in Rheumatoid Arthritis: Inflammation, Arterial Stiffness and Circulating Progenitor Cell Number.
(2015/04) Vitamin D status and its association with quality of life, physical activity, and disease activity in rheumatoid arthritis patients.
(2012/12) Clinical review: Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies.
(2012/10) Vitamin d, metabolic dyslipidemia, and metabolic syndrome in rheumatoid arthritis.
(2011/12) Unsuppressed parathyroid hormone in patients with autoimmune/inflammatory rheumatic diseases: implications for vitamin D supplementation.
(2011/01) Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity.
(2010/09) Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis.
Nerve Health
(2017/05) Role for a water-soluble form of CoQ10 in female subjects affected by fibromyalgia. A preliminary study.
(2013/04) Can Coenzyme Q10 Improve Clinical and Molecular Parameters in Fibromyalgia?
(2009/05) Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia
(2002/03) An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome
(2017/12) Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis.
(2017/09) The relationship between balance and vitamin 25(OH)D in fibromyalgia patients.
(2017/02) Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial.
(2016/03) Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome.
(2015/09) Is Serum Hypovitaminosis D Associated with Chronic Widespread Pain Including Fibromyalgia? A Meta-analysis of Observational Studies.
(2014/02) Effects of vitamin D on patients with fibromyalgia syndrome: A randomized placebo-controlled trial.
(2013/12) Fibromyalgia syndrome: is it related to vitamin D deficiency in premenopausal female patients?
Systemic Lupus Erythematosus (SLE)
(2010/06) Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
(2008/08) Dehydroepiandrosterone in systemic lupus erythematosus.
(2008/08) Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
(2007/10) Dehydroepiandrosterone for systemic lupus erythematosus.
(2005/11) DHEA supplementation: the claims in perspective.
(2004/12) Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.
(2004/11) The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
(2004/09) Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
(2002/11) Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
(2002/07) Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
(2002/01) Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.
(2017/11) Omega-3 fatty acids, inflammatory status and biochemical markers of patients with systemic lupus erythematosus: a pilot study.
(2017/09) Omega-3 Fatty Acids in Rheumatic Diseases: A Critical Review.
(2015/08) Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus.
(2015/02) Fish oil N-3 fatty acids increase adiponectin and decrease leptin levels in patients with systemic lupus erythematosus.
(2013/11) Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus.
(2008/06) A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus
(2004/08) The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus.
(2018/08) The Impact of Vitamin D on the Immunopathophysiology, Disease Activity, and Extra-Musculoskeletal Manifestations of Systemic Lupus Erythematosus.
(2018/07) Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysis.
(2017/11) Bone mineral density and vitamin D status in systemic lupus erythematosus (SLE): A systematic review.
(2017/09) Effect of vitamin D supplementation on patients with systemic lupus erythematosus: a systematic review.
(2017/08) Serum 25-OH vitamin D level in treatment-naïve systemic lupus erythematosus patients: Relation to disease activity, IL-23 and IL-17.
(2017/01) 25-Hydroxivitamin D Serum Concentration, Not Free and Bioavailable Vitamin D, Is Associated with Disease Activity in Systemic Lupus Erythematosus Patients.
(2012/10) Premature Atherosclerosis Is Associated With Hypovitaminosis D and Angiotensin-Converting Enzyme Inhibitor Non-use in Lupus Patients.
(2012/04) Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters.
(2012/04) Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis.
(2011/12) Unsuppressed parathyroid hormone in patients with autoimmune/inflammatory rheumatic diseases: implications for vitamin D supplementation.
(2011/09) Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus.
(2010/08) Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage.
(2010/06) Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
(2010/02) The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus.
(2010/01) Vitamin D insufficiency in a large female SLE cohort.
(2009/10) 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus.
(2008/06) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences.
